CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intest Res. 2019;17(3):340-348.   Published online May 31, 2019
DOI: https://doi.org/10.5217/ir.2019.00012

Excel Download

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Intestinal Research. 2019;17(3):340-348   Crossref logo
Link1 Link2 Link3

Ustekinumab success in refractory Crohn’s disease
Springer Healthcare News. 2012;1(1):   Crossref logo
Link1 Link2 Link3

AF.60 A PILOT STUDY ON THE USE OF USTEKINUMAB IN REFRACTORY PERIANAL CROHN’S DISEASE
Digestive and Liver Disease. 2021;53:S164   Crossref logo
Link1 Link2

Is Ustekinumab Effective in Refractory Crohn’s Disease of the Pouch and Chronic Pouchitis? A Systematic Review
Digestive Diseases and Sciences. 2021;   Crossref logo
Link1 Link2 Link3

Ustekinumab is a Safe and Effective Biological Agent for Crohn’s Disease in a Liver Transplant Patient
Journal of Crohn's and Colitis. 2020;14(10):1498-1499   Crossref logo
Link1 Link2 Link3

P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S379-S379   Crossref logo
Link1 Link2

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
Journal of the Canadian Association of Gastroenterology. 2019;   Crossref logo
Link1

The Fecal Microbiome as a Tool for Monitoring and Predicting Response Outcomes in Ustekinumab-Treated, Anti-TNFî‘ Refractory Crohn’s Disease Patients: Results from the Certifi Study
Gastroenterology. 2017;152(5):S191   Crossref logo
Link1 Link2

Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn’s Disease
Journal of Crohn's and Colitis. 2021;15(8):1399-1400   Crossref logo
Link1 Link2 Link3

OC.09.5 LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN’S DISEASE: A MULTICENTER REALLIFE STUDY
Digestive and Liver Disease. 2021;53:S129   Crossref logo
Link1 Link2